Regeneron Pharmaceuticals | REGN - Net Income


Regeneron Pharmaceuticals reported $1.3B in Net Income for its fiscal quarter ending in June of 2026.





Net Income Change Date
AbbVie USD 4.22B 605M Sep/2026
Agenus USD 39.17M 49.8M Mar/2026
Agios Pharmaceuticals USD -100.7M 1.59M Jun/2026
Alnylam Pharmaceuticals USD 2.17B 2B Sep/2026
Amgen USD 3.86B 1.49B Sep/2026
Astellas Pharma JPY 99.85B 41.98B Sep/2026
AstraZeneca USD 3.12B 610M Sep/2026
Biogen USD 97.5M 222M Jun/2026
BioMarin Pharmaceutical USD -122.83M 167.59M Sep/2026
Bristol-Myers Squibb USD 2.16B 1.16B Sep/2026
Eli Lilly USD 7.1B 301M Jun/2026
Gilead Sciences USD -10.5B 12.52B Jun/2026
GlaxoSmithKline GBP 1.54B 1.11B Sep/2026
Incyte USD -784.8M 1.37B Sep/2026
Ionis Pharmaceuticals USD -114.65M 21.65M Jun/2026
J&J USD 210M 5.32B Sep/2026
Kyowa Hakko Kirin JPY 21.06B 2.47B Sep/2026
Merck USD 5.07B 6.4B Sep/2026
Moderna USD -1.34B 517M Mar/2026
Neurocrine Biosciences USD 144.4M 53.5M Jun/2026
Novartis USD 1.2B 2.06B Sep/2026
Novartis USD 1.2B 1.95B Sep/2026
Pfizer USD 3.24B 3.49B Sep/2026
Puma Biotechnology USD 20.32M 24.85M Sep/2024
Regeneron Pharmaceuticals USD 1.3B 569.7M Jun/2026
Roche Holding CHF 6.87B 1.4B Jun/2026
Sanofi EUR 343M 1.27B Jun/2026
Sarepta Therapeutics USD -4.89M 335.85M Jun/2026
Teva Pharmaceutical Industries USD 233M 809M Sep/2026
Ultragenyx Pharmaceutical USD -118M 26M Sep/2026
United Therapeutics USD 258.6M 74.4M Sep/2026
Vertex Pharmaceuticals USD 653.6M 446.2M Sep/2026